Lonza Plans Biologics Manufacturing Expansion
Lonza Plans Biologics Manufacturing Expansion
Lonza (Basel, Switzerland, www.lonza.com), a custom manufacturer of small molecules, intermediates, and biologics, is planning to expand its biologics manufacturing facility in Portsmouth, New Hampshire, to provide new mid-scale capacity. The groundbreaking for the 5000-L reactors is scheduled for April 2006.
The expansion follows recent investment in the company’s bioreactor capacity. The fourth 20,000-L bioreactor in Portsmouth is slated to become operational in mid-2006. Lonza’s manufacturing portfolio consists of 2000, 5000 and 20,000-L bioreactors. The increased capacity in the mid-scale also will accommodate preclinical production needs.
The new biologics capacity follows Lonza’s acquisition last month of
UCB Bioproducts
(Braine-l’Alleud, Belgium,
www.ucb-bioproducts.com
), the bioproducts manufacturing division of the biopharmaceutical company
UCB
(Brussels, Belgium,
www.ucb-group.com
).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
